MX2016003653A - Virus de mosaico de papaya y particulas similares a virus en terapia de cancer. - Google Patents
Virus de mosaico de papaya y particulas similares a virus en terapia de cancer.Info
- Publication number
- MX2016003653A MX2016003653A MX2016003653A MX2016003653A MX2016003653A MX 2016003653 A MX2016003653 A MX 2016003653A MX 2016003653 A MX2016003653 A MX 2016003653A MX 2016003653 A MX2016003653 A MX 2016003653A MX 2016003653 A MX2016003653 A MX 2016003653A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- particles
- cancer therapy
- papaya mosaic
- mosaic virus
- Prior art date
Links
- 241000709995 Papaya mosaic virus Species 0.000 title abstract 4
- 238000011275 oncology therapy Methods 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/40011—Tymoviridae
- C12N2770/40021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/40011—Tymoviridae
- C12N2770/40023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/40011—Tymoviridae
- C12N2770/40033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/40011—Tymoviridae
- C12N2770/40034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/40011—Tymoviridae
- C12N2770/40041—Use of virus, viral particle or viral elements as a vector
- C12N2770/40042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361880156P | 2013-09-19 | 2013-09-19 | |
| US201361886481P | 2013-10-03 | 2013-10-03 | |
| PCT/CA2014/050908 WO2015039255A1 (en) | 2013-09-19 | 2014-09-19 | Papaya mosaic virus and virus-like particles in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003653A true MX2016003653A (es) | 2016-08-11 |
Family
ID=52688058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003653A MX2016003653A (es) | 2013-09-19 | 2014-09-19 | Virus de mosaico de papaya y particulas similares a virus en terapia de cancer. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160228541A1 (enExample) |
| EP (1) | EP3046565A4 (enExample) |
| JP (1) | JP2016531927A (enExample) |
| CN (1) | CN105899217A (enExample) |
| CA (1) | CA2924819A1 (enExample) |
| MX (1) | MX2016003653A (enExample) |
| WO (1) | WO2015039255A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10086095B2 (en) | 2012-10-09 | 2018-10-02 | Case Western Reserve University | Rod-shaped plant virus nanoparticles as imaging agent platforms |
| WO2014113203A1 (en) | 2013-01-17 | 2014-07-24 | Case Western Reserve University | Viral nanoparticle multimers |
| US9925281B2 (en) | 2014-08-05 | 2018-03-27 | Case Western Reserve University | Coated plant virus imaging agents |
| WO2016073972A1 (en) | 2014-11-07 | 2016-05-12 | Case Western Reserve University | Cancer immunotherapy using virus particles |
| WO2017004123A1 (en) | 2015-06-29 | 2017-01-05 | Case Western Reserve University | Anticancer drug-containing plant virus particles |
| US10478510B2 (en) | 2015-07-16 | 2019-11-19 | Case Western Resrve University | Plant virus particles for delivery of antimitotic agents |
| WO2017210682A1 (en) | 2016-06-03 | 2017-12-07 | Case Western Reserve University | Rod-shaped plant viral nanoparticles or virus-like particles for agricultural applications |
| EP3487527A4 (en) | 2016-07-21 | 2020-03-11 | Case Western Reserve University | Plant virus or virus-like particle constructs |
| US12433840B2 (en) | 2016-11-03 | 2025-10-07 | Case Western Reserve University | Melt processed viral nanoparticle constructs |
| EP3535283A4 (en) | 2016-11-03 | 2020-08-12 | Case Western Reserve University | CONSTRUCTIONS OF FUSION TREATED VIRAL NANOPARTICLES |
| US11590183B2 (en) | 2017-03-10 | 2023-02-28 | Case Western Reserve University | Cancer immunotherapy using virus particles |
| WO2018213587A1 (en) | 2017-05-17 | 2018-11-22 | Case Western Reserve University | Anticancer trail-targeted plant virus particles |
| US11739301B2 (en) | 2017-10-27 | 2023-08-29 | Case Western Reserve University | Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents |
| US11390853B2 (en) | 2019-04-26 | 2022-07-19 | Case Western Reserve University | Freeze dried viral nanoparticle constructs |
| US11896676B2 (en) | 2019-08-07 | 2024-02-13 | Case Western Reserve University | Targeting cancer cells and tissue using filamentous plant virus particles |
| US12203073B2 (en) | 2019-12-20 | 2025-01-21 | Case Western Reserve University | Plant viral RNA delivery nanoparticles and uses thereof |
| US11529430B2 (en) | 2019-12-20 | 2022-12-20 | Case Western Reserve University | Polydopamine decorated tobacco mosaic theranostic virus nanoparticles |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101189B2 (en) * | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| MXPA05000287A (es) * | 2002-07-05 | 2005-09-08 | Leclerc Denis | Particula viral adyuvante. |
| DK2707480T3 (da) * | 2011-05-13 | 2017-11-13 | Folia Biotech Inc | Viruslignende partikler og fremgangsmåde til fremstilling heraf |
-
2014
- 2014-09-19 WO PCT/CA2014/050908 patent/WO2015039255A1/en not_active Ceased
- 2014-09-19 US US15/022,907 patent/US20160228541A1/en not_active Abandoned
- 2014-09-19 JP JP2016543278A patent/JP2016531927A/ja active Pending
- 2014-09-19 CN CN201480057495.XA patent/CN105899217A/zh active Pending
- 2014-09-19 MX MX2016003653A patent/MX2016003653A/es unknown
- 2014-09-19 EP EP14846668.3A patent/EP3046565A4/en not_active Withdrawn
- 2014-09-19 CA CA2924819A patent/CA2924819A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3046565A1 (en) | 2016-07-27 |
| WO2015039255A1 (en) | 2015-03-26 |
| EP3046565A4 (en) | 2017-06-28 |
| US20160228541A1 (en) | 2016-08-11 |
| CA2924819A1 (en) | 2015-03-26 |
| JP2016531927A (ja) | 2016-10-13 |
| CN105899217A (zh) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252970A0 (en) | Compositions and methods for high efficiency in vivo genome editing | |
| MX2021004479A (es) | Agentes biologicos y su uso en plantas. | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2017002050A1 (es) | Uso de plinabulina en combinación con inhibidores de punto de control inmunitario | |
| CL2016000373A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
| PH12015502087B1 (en) | Newcastle disease viruses and uses thereof | |
| CL2016000381A1 (es) | Compuestos antivirales | |
| MX378792B (es) | Células hospederas modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados. | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
| CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
| EP3046565A4 (en) | Papaya mosaic virus and virus-like particles in cancer therapy | |
| SMT202400465T1 (it) | Metodi per produrre cellule t autologhe utili per trattare malignità a cellule b e altri cancri e loro composizioni | |
| MX370573B (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. | |
| MY181994A (en) | Immuno-modulatory progenitor (imp) cell | |
| MX374915B (es) | Uso de excipientes polimericos para liofilizacion o congelacion de particulas. | |
| MX2015016406A (es) | Formulacion de revestimiento para madera. | |
| MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| IL258342A (en) | Increased gene delivery to natural killer cells, hematopoietic stem cells and macrophages | |
| DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CO2017011964A2 (es) | Un metodo para producir hcg recombinante | |
| EP3220913A4 (en) | Novel nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| CL2013003198A1 (es) | Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas. |